作者: Jan Korabecny , Katarina Spilovska , Eva Mezeiova , Ondrej Benek , Radomir Juza
DOI: 10.2174/0929867325666180517094023
关键词: Cholinesterase 、 Memantine 、 Rivastigmine 、 Medicine 、 Acetylcholinesterase 、 Pharmacology 、 Donepezil 、 Butyrylcholinesterase 、 Tacrine 、 Galantamine
摘要: Alzheimer's Disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach approved for the treatment AD. The pharmacotherapy AD relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, acetylcholinesterase (AChE) inhibitors (AChEIs) tacrine, donepezil, rivastigmine galantamine. Donepezil was able to ameliorate symptoms related mainly via AChE, but also through reduction β-amyloid burden. This review presents overview donepezilrelated compounds as potential anti-AD drugs developed basis cholinergic hypothesis act solely AChE butyrylcholinesterase (BChE) inhibitors.